A single-arm phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive ovarian cancer patients previously treated with a PARP inhibitor
Trial Number
NCT04734665 (ClinicalTrials.gov Identifier)Contact Person
Status
Recruiting
Disease Site
Recurrent Ovarian